Wednesday, October 3, 2012

Evolving Pharma Sales Models: The Customer is King

How pharmaceutical, biotechnology, and medical device products are sold is changing and it will continue to do so for the foreseeable future. There are many factors driving this change, and two of the most significant are healthcare reform changes and that healthcare providers are demanding meaningful interactions with company representatives. Life science companies are developing new sales models that aren’t solely a “sales pitch”. Rather, the interaction is “customer-centric” and based on meeting the customer’s needs and providing value.

Evolving your sales model to be focused on meeting customer needs is much more than just adapting your sales messages to address the latest concerns heard in the field. This is a fundamental mindset change, and life sciences companies have think about what it is they are offering and delivering. In the future our healthcare system will be focused on patient outcomes and cost. This environment requires the life science industry to provide programs that support treatments to improve patient outcomes, provide value, and decrease costs.

Patient adherence is an important driver in improving patient outcomes and decreasing future healthcare costs, but it is not the only one. In many disease-states and conditions there are health, wellness, and lifestyle factors that contribute to long-term improvement in outcomes and decreases in healthcare expenditures. There is an opportunity, and need, for life sciences companies to partner with patients, providers, and payers to address health, wellness, and lifestyle factors.

There are many programs that can be developed and implemented that will improve patient outcomes. To create meaningful programs patients can “stick to”, think about these areas…

* Understand the barriers patients face in remaining adherent and compliant with therapy.

* Plan programs that support patients on their treatment journey, and help them adhere to treatment.

* Develop patient support programs that are a resource and guide for patients during their treatment journey.
I encourage you to think holistically about the challenges of patients, providers, and payers and design programs to meet these broad needs. As life science companies look to evolve their sales models to meet customers’ needs and provide meaningful interactions, the need for programs that support patients, providers, and payers will increase. Provide solutions, through your product and its related services, to manage or overcome the broad healthcare challenges your customers face.

There are many options for providing programs that enhance patient outcomes. As a pharmaceutical call center, we provide as needed call-in support for patients, caregivers, and healthcare providers to answer questions about a product and its side effects, enroll patients in a support program, connect patients with healthcare providers in their local area, and connect patients with co-pay assistance resources. Our experiences show that within 6 months of implementing a patient support program patient adherence increases 10% to 15%. Patient adherence to treatment decreases future healthcare costs related to treating complications from earlier non-adherence.

There was an interesting article recently published on Pharmaceutical Executive on-line that looks at the evolving nature of pharmaceutical sales forces as they evolve to a more “customer-centric” approach. If you are interested in learning more about one model for moving in this direction you can access the article here.

I’d like to hear from you. Are you adding programs to support patients as a part of your marketing and sales efforts? If you are, what kinds of initiatives and programs are you planning? Please join the conversation and share your thoughts and challenges. We can all learn from each other. Alternatively, if you have specific needs you’d like to discuss with me you can reach me directly at louis.shapiro@tunstallamac.com.

View full blog

View website for Tunstall AMAC Life Sciences  

1 comment:

  1. Thanks for the note, Dyan. Clearly, this is an important topic and will become even more critical for pharma in the near future.

    ReplyDelete